Day: March 29, 2021

SOUTH SAN FRANCISCO, Calif., March 29, 2021 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares in the proposed offering will be sold by AMT. In addition, AMT expects to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering. BofA Securities, Jefferies, and SVB Leerink are acting as joint book-running managers for the proposed offering. A registration statement relating...

~ Company intends to repurchase shares opportunistically ~ ~ Previous communicated growth outlook remains unchanged~ LA JOLLA, Calif., March 29, 2021 (GLOBE NEWSWIRE) — Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or the “Company”) today announced that its Board of Directors has approved a share repurchase program effective March 31, 2021. The program authorizes the repurchase by the Company of up to $40 million of its outstanding shares of common stock over the period ending on March 31, 2023. Under the share repurchase program, shares may be repurchased from time to time in the open market or negotiated transactions at prevailing market rates, or by other means in accordance with federal securities laws. Mac Armstrong, Chairman and Chief Executive Officer of Palomar, commented, “The Board’s authorization of the share repurchase...

FOSTER CITY, Calif., March 29, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update. “The past year has been transformational for Vaxcyte and I am pleased with the multiple milestones we have achieved on the path to submit our Investigational New Drug (IND) application for VAX-24, our 24-valent pneumococcal conjugate vaccine (PCV), the progress of our other pipeline programs, and the addition of new leadership team members,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “While...

Fourth Quarter 2020 Highlights and Recent DevelopmentsContinued focus on centralizing key resources and improving utilizationPreviously announced closure of Jennings facility completed in the fourth quarter 2020 Closure of Lake Charles facility announced and completed in the fourth quarter 2020Improved performance for the Fabrication & Services Division Final two harbor tugs completed within the Shipyard Division Change order finalized with the U.S. Navy in March 2021, providing anticipated first quarter 2021 benefitHOUSTON, March 29, 2021 (GLOBE NEWSWIRE) — Gulf Island Fabrication, Inc. (“Gulf Island” or the “Company”) (NASDAQ: GIFI) today reported results for the fourth quarter and full year 2020.Operating Results(in thousands, except per share data)   Three Months Ended December 31,     Years...

NEW HAVEN, Conn., March 29, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the publication of research validating the ability of the company’s xB3 ™ platform to efficiently deliver siRNA across the blood-brain barrier to the central nervous system in therapeutically relevant doses. Scientists from Bioasis and Dr. Wilfred A. Jefferies evaluated Bioasis’ xB3 ™ platform technology by investigating its application to siRNA brain...

Crystal Bay, Nevada, March 29, 2021 (GLOBE NEWSWIRE) — Evo Acquisition Corp. (NASDAQ: EVOJU) (the “Company”) announced that, commencing April 1, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s Class A common stock and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The shares of Class A common stock and warrants that are separated will trade on the Nasdaq Capital Market under the symbols “EVOJ” and “EVOJW,” respectively. Those units not separated will continue to trade on the Nasdaq Capital Market under the symbol “EVOJU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to...

DAYTONA BEACH, Fla., March 29, 2021 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) announced today that it will report its financial and operating results for the first quarter 2021 after the market closes on Thursday, April 22, 2021. A conference call to discuss its financial and operating results is scheduled for Friday, April 23, 2021 at 9:00 AM ET (the “Earnings Call”). Shareholders and interested parties may access the Earnings Call via teleconference or webcast:Teleconference: USA (Toll Free) 1-888-317-6003  International 1-412-317-6061  Canada (Toll Free) 1-855-669-9657To access the conference call, enter 0658375 when prompted. To participate via teleconference, please dial-in approximately 10 minutes prior to the scheduled time of the Earnings Call. To access the webcast, log...

Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers Progress towards IND filing for KIN-2787, our RAF inhibitor candidate, in the first half of 2021 and initiating a Phase 1 clinical trial later in the year remains on track Selected KIN-3248 as our lead FGFR inhibitor candidate; anticipate IND filing in the first half of 2022 SAN FRANCISCO and SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the full year ended December 31, 2020. “Since completing our IPO last year, we entered 2021 well-funded to advance the development of our lead...